ID   GCYA3_HUMAN             Reviewed;         690 AA.
AC   Q02108; D3DP19; D6RDW3; O43843; Q8TAH3;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   10-MAY-2017, entry version 163.
DE   RecName: Full=Guanylate cyclase soluble subunit alpha-3;
DE            Short=GCS-alpha-3;
DE            EC=4.6.1.2 {ECO:0000269|PubMed:23505436, ECO:0000269|PubMed:24669844, ECO:0000269|PubMed:9742212};
DE   AltName: Full=GCS-alpha-1;
DE   AltName: Full=Soluble guanylate cyclase large subunit;
GN   Name=GUCY1A3; Synonyms=GUC1A3, GUCSA3, GUCY1A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=1352257; DOI=10.1016/0014-5793(92)80594-7;
RA   Giuili G., Scholl U., Bulle F., Guellaeen G.;
RT   "Molecular cloning of the cDNAs coding for the two subunits of soluble
RT   guanylyl cyclase from human brain.";
RL   FEBS Lett. 304:83-88(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RA   Gansemans Y., Brouckaert P., Fiers W.;
RT   "Human soluble guanylate cyclase large subunit mRNA, alpha3-like.";
RL   Submitted (MAY-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, ENZYME
RP   REGULATION, SUBUNIT, INTERACTION WITH GUCY1B3, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=9742212; DOI=10.1042/bj3350051;
RA   Zabel U., Weeger M., La M., Schmidt H.H.;
RT   "Human soluble guanylate cyclase: functional expression and revised
RT   isoenzyme family.";
RL   Biochem. J. 335:51-57(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8] {ECO:0000244|PDB:3UVJ}
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 468-690 IN COMPLEX WITH
RP   GUCY1B3, CATALYTIC ACTIVITY, ENZYME REGULATION, COFACTOR, AND
RP   INTERACTION WITH GUCY1B3.
RX   PubMed=23505436; DOI=10.1371/journal.pone.0057644;
RA   Allerston C.K., von Delft F., Gileadi O.;
RT   "Crystal structures of the catalytic domain of human soluble guanylate
RT   cyclase.";
RL   PLoS ONE 8:E57644-E57644(2013).
RN   [9]
RP   INVOLVEMENT IN MYMY6.
RX   PubMed=24581742; DOI=10.1016/j.ajhg.2014.01.018;
RA   Herve D., Philippi A., Belbouab R., Zerah M., Chabrier S.,
RA   Collardeau-Frachon S., Bergametti F., Essongue A., Berrou E.,
RA   Krivosic V., Sainte-Rose C., Houdart E., Adam F., Billiemaz K.,
RA   Lebret M., Roman S., Passemard S., Boulday G., Delaforge A., Guey S.,
RA   Dray X., Chabriat H., Brouckaert P., Bryckaert M.,
RA   Tournier-Lasserve E.;
RT   "Loss of alpha1beta1 soluble guanylate cyclase, the major nitric oxide
RT   receptor, leads to moyamoya and achalasia.";
RL   Am. J. Hum. Genet. 94:385-394(2014).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 468-662 IN COMPLEX WITH
RP   GUCY1B3, INTERACTION WITH GUCY1B3, CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=24669844; DOI=10.1021/bi500129k;
RA   Seeger F., Quintyn R., Tanimoto A., Williams G.J., Tainer J.A.,
RA   Wysocki V.H., Garcin E.D.;
RT   "Interfacial residues promote an optimal alignment of the catalytic
RT   center in human soluble guanylate cyclase: heterodimerization is
RT   required but not sufficient for activity.";
RL   Biochemistry 53:2153-2165(2014).
CC   -!- CATALYTIC ACTIVITY: GTP = 3',5'-cyclic GMP + diphosphate.
CC       {ECO:0000269|PubMed:23505436, ECO:0000269|PubMed:24669844,
CC       ECO:0000269|PubMed:9742212}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:23505436,
CC         ECO:0000269|PubMed:24669844};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:23505436,
CC         ECO:0000269|PubMed:24669844};
CC       Note=Has also activity with Mn(2+) (in vitro).
CC       {ECO:0000269|PubMed:23505436, ECO:0000269|PubMed:24669844};
CC   -!- ENZYME REGULATION: Activated by nitric oxide in the presence of
CC       magnesium or manganese ions. {ECO:0000269|PubMed:9742212}.
CC   -!- SUBUNIT: The active enzyme is formed by a heterodimer of an alpha
CC       and a beta subunit. Heterodimer with GUCY1B3 (PubMed:9742212,
CC       PubMed:23505436, PubMed:24669844). {ECO:0000269|PubMed:23505436,
CC       ECO:0000269|PubMed:24669844, ECO:0000269|PubMed:9742212}.
CC   -!- INTERACTION:
CC       Q02153:GUCY1B3; NbExp=2; IntAct=EBI-3910037, EBI-6911707;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q02108-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q02108-2; Sequence=VSP_045477;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in brain cortex and lung (at protein
CC       level). {ECO:0000269|PubMed:1352257}.
CC   -!- DISEASE: Moyamoya disease 6 with achalasia (MYMY6) [MIM:615750]: A
CC       form of Moyamoya disease, a progressive cerebral angiopathy
CC       characterized by bilateral intracranial carotid artery stenosis
CC       and telangiectatic vessels in the region of the basal ganglia. The
CC       abnormal vessels resemble a 'puff of smoke' (moyamoya) on cerebral
CC       angiogram. Affected individuals can develop transient ischemic
CC       attacks and/or cerebral infarction, and rupture of the collateral
CC       vessels can cause intracranial hemorrhage. Hemiplegia of sudden
CC       onset and epileptic seizures constitute the prevailing
CC       presentation in childhood, while subarachnoid bleeding occurs more
CC       frequently in adults. MYMY6 is characterized by severe cerebral
CC       angiopathy and onset of severe achalasia in infancy or early
CC       childhood. {ECO:0000269|PubMed:24581742}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: There are two types of guanylate cyclases: soluble
CC       forms and membrane-associated receptor forms.
CC   -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl
CC       cyclase family. {ECO:0000255|PROSITE-ProRule:PRU00099}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA47145.1; Type=Frameshift; Positions=123, 127, 131, 162, 184, 529, 535, 678, 680; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X66534; CAA47145.1; ALT_FRAME; mRNA.
DR   EMBL; U58855; AAB94794.1; -; mRNA.
DR   EMBL; Y15723; CAA75738.1; -; mRNA.
DR   EMBL; AK309950; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC104083; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471056; EAX04892.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04895.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04896.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04897.1; -; Genomic_DNA.
DR   EMBL; BC028384; AAH28384.1; -; mRNA.
DR   CCDS; CCDS34085.1; -. [Q02108-1]
DR   CCDS; CCDS54812.1; -. [Q02108-2]
DR   PIR; S23098; S23098.
DR   RefSeq; NP_000847.2; NM_000856.5. [Q02108-1]
DR   RefSeq; NP_001124154.1; NM_001130682.2. [Q02108-1]
DR   RefSeq; NP_001124155.1; NM_001130683.3. [Q02108-1]
DR   RefSeq; NP_001124156.1; NM_001130684.2. [Q02108-1]
DR   RefSeq; NP_001124159.1; NM_001130687.2. [Q02108-2]
DR   RefSeq; NP_001243378.1; NM_001256449.1. [Q02108-1]
DR   RefSeq; XP_005263012.1; XM_005262955.2. [Q02108-1]
DR   RefSeq; XP_006714259.1; XM_006714196.2. [Q02108-1]
DR   RefSeq; XP_006714260.1; XM_006714197.2. [Q02108-1]
DR   UniGene; Hs.24258; -.
DR   UniGene; Hs.740815; -.
DR   PDB; 3UVJ; X-ray; 2.08 A; A/C=468-690.
DR   PDB; 4NI2; X-ray; 1.90 A; A=468-662.
DR   PDBsum; 3UVJ; -.
DR   PDBsum; 4NI2; -.
DR   ProteinModelPortal; Q02108; -.
DR   SMR; Q02108; -.
DR   BioGrid; 109237; 9.
DR   IntAct; Q02108; 3.
DR   STRING; 9606.ENSP00000296518; -.
DR   BindingDB; Q02108; -.
DR   ChEMBL; CHEMBL3137281; -.
DR   GuidetoPHARMACOLOGY; 1288; -.
DR   iPTMnet; Q02108; -.
DR   PhosphoSitePlus; Q02108; -.
DR   BioMuta; GUCY1A3; -.
DR   DMDM; 7404351; -.
DR   EPD; Q02108; -.
DR   MaxQB; Q02108; -.
DR   PaxDb; Q02108; -.
DR   PeptideAtlas; Q02108; -.
DR   PRIDE; Q02108; -.
DR   DNASU; 2982; -.
DR   Ensembl; ENST00000296518; ENSP00000296518; ENSG00000164116. [Q02108-1]
DR   Ensembl; ENST00000455639; ENSP00000412201; ENSG00000164116. [Q02108-1]
DR   Ensembl; ENST00000506455; ENSP00000424361; ENSG00000164116. [Q02108-1]
DR   Ensembl; ENST00000511108; ENSP00000421493; ENSG00000164116. [Q02108-1]
DR   Ensembl; ENST00000511507; ENSP00000426968; ENSG00000164116. [Q02108-2]
DR   Ensembl; ENST00000513574; ENSP00000426040; ENSG00000164116. [Q02108-1]
DR   GeneID; 2982; -.
DR   KEGG; hsa:2982; -.
DR   UCSC; uc003iov.4; human. [Q02108-1]
DR   CTD; 2982; -.
DR   DisGeNET; 2982; -.
DR   GeneCards; GUCY1A3; -.
DR   HGNC; HGNC:4685; GUCY1A3.
DR   HPA; CAB010887; -.
DR   HPA; HPA056004; -.
DR   MalaCards; GUCY1A3; -.
DR   MIM; 139396; gene.
DR   MIM; 615750; phenotype.
DR   neXtProt; NX_Q02108; -.
DR   OpenTargets; ENSG00000164116; -.
DR   Orphanet; 401945; Moyamoya disease with early-onset achalasia.
DR   PharmGKB; PA29067; -.
DR   eggNOG; KOG4171; Eukaryota.
DR   eggNOG; COG2114; LUCA.
DR   GeneTree; ENSGT00760000118959; -.
DR   HOGENOM; HOG000220903; -.
DR   HOVERGEN; HBG106603; -.
DR   InParanoid; Q02108; -.
DR   KO; K12318; -.
DR   OMA; SEIPGIC; -.
DR   OrthoDB; EOG091G04KV; -.
DR   PhylomeDB; Q02108; -.
DR   TreeFam; TF351403; -.
DR   BRENDA; 4.6.1.2; 2681.
DR   Reactome; R-HSA-392154; Nitric oxide stimulates guanylate cyclase.
DR   SIGNOR; Q02108; -.
DR   ChiTaRS; GUCY1A3; human.
DR   GeneWiki; GUCY1A3; -.
DR   GenomeRNAi; 2982; -.
DR   PRO; PR:Q02108; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000164116; -.
DR   CleanEx; HS_GUCY1A3; -.
DR   ExpressionAtlas; Q02108; baseline and differential.
DR   Genevisible; Q02108; HS.
DR   GO; GO:0008074; C:guanylate cyclase complex, soluble; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004383; F:guanylate cyclase activity; IDA:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IEA:InterPro.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0006182; P:cGMP biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; TAS:ProtInc.
DR   GO; GO:0030828; P:positive regulation of cGMP biosynthetic process; IEA:Ensembl.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0060087; P:relaxation of vascular smooth muscle; IEA:Ensembl.
DR   GO; GO:0052565; P:response to defense-related host nitric oxide production; IEA:Ensembl.
DR   Gene3D; 3.30.70.1230; -; 1.
DR   InterPro; IPR001054; A/G_cyclase.
DR   InterPro; IPR018297; A/G_cyclase_CS.
DR   InterPro; IPR011644; Heme_NO-bd.
DR   InterPro; IPR011645; HNOB_dom_associated.
DR   InterPro; IPR024096; NO_sig/Golgi_transp_ligand-bd.
DR   InterPro; IPR029787; Nucleotide_cyclase.
DR   Pfam; PF00211; Guanylate_cyc; 1.
DR   Pfam; PF07700; HNOB; 1.
DR   Pfam; PF07701; HNOBA; 1.
DR   SMART; SM00044; CYCc; 1.
DR   SUPFAM; SSF111126; SSF111126; 1.
DR   SUPFAM; SSF55073; SSF55073; 1.
DR   PROSITE; PS00452; GUANYLATE_CYCLASE_1; 1.
DR   PROSITE; PS50125; GUANYLATE_CYCLASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; cGMP biosynthesis;
KW   Complete proteome; Cytoplasm; GTP-binding; Lyase; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    690       Guanylate cyclase soluble subunit alpha-
FT                                3.
FT                                /FTId=PRO_0000074110.
FT   DOMAIN      481    608       Guanylate cyclase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00099}.
FT   MOD_RES     267    267       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9ERL9}.
FT   VAR_SEQ     625    690       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045477.
FT   VARIANT      25     25       V -> I (in dbSNP:rs2170646).
FT                                /FTId=VAR_049257.
FT   CONFLICT     44     44       V -> M (in Ref. 7; AAH28384).
FT                                {ECO:0000305}.
FT   CONFLICT    124    127       AAGV -> QQS (in Ref. 1; CAA47145).
FT                                {ECO:0000305}.
FT   CONFLICT    322    322       Missing (in Ref. 1; CAA47145).
FT                                {ECO:0000305}.
FT   CONFLICT    497    497       C -> R (in Ref. 4; AK309950).
FT                                {ECO:0000305}.
FT   CONFLICT    554    554       L -> V (in Ref. 7; AAH28384).
FT                                {ECO:0000305}.
FT   STRAND      472    487       {ECO:0000244|PDB:4NI2}.
FT   HELIX       490    496       {ECO:0000244|PDB:4NI2}.
FT   HELIX       499    519       {ECO:0000244|PDB:4NI2}.
FT   STRAND      523    525       {ECO:0000244|PDB:4NI2}.
FT   STRAND      533    540       {ECO:0000244|PDB:4NI2}.
FT   HELIX       545    560       {ECO:0000244|PDB:4NI2}.
FT   STRAND      568    570       {ECO:0000244|PDB:4NI2}.
FT   STRAND      573    587       {ECO:0000244|PDB:4NI2}.
FT   STRAND      589    591       {ECO:0000244|PDB:4NI2}.
FT   STRAND      593    598       {ECO:0000244|PDB:4NI2}.
FT   HELIX       599    609       {ECO:0000244|PDB:4NI2}.
FT   STRAND      616    618       {ECO:0000244|PDB:4NI2}.
FT   HELIX       620    626       {ECO:0000244|PDB:4NI2}.
FT   STRAND      632    636       {ECO:0000244|PDB:4NI2}.
FT   STRAND      655    660       {ECO:0000244|PDB:4NI2}.
SQ   SEQUENCE   690 AA;  77452 MW;  DA1E14A5E11451CF CRC64;
     MFCTKLKDLK ITGECPFSLL APGQVPNESS EEAAGSSESC KATVPICQDI PEKNIQESLP
     QRKTSRSRVY LHTLAESICK LIFPEFERLN VALQRTLAKH KIKESRKSLE REDFEKTIAE
     QAVAAGVPVE VIKESLGEEV FKICYEEDEN ILGVVGGTLK DFLNSFSTLL KQSSHCQEAG
     KRGRLEDASI LCLDKEDDFL HVYYFFPKRT TSLILPGIIK AAAHVLYETE VEVSLMPPCF
     HNDCSEFVNQ PYLLYSVHMK STKPSLSPSK PQSSLVIPTS LFCKTFPFHF MFDKDMTILQ
     FGNGIRRLMN RRDFQGKPNF EEYFEILTPK INQTFSGIMT MLNMQFVVRV RRWDNSVKKS
     SRVMDLKGQM IYIVESSAIL FLGSPCVDRL EDFTGRGLYL SDIPIHNALR DVVLIGEQAR
     AQDGLKKRLG KLKATLEQAH QALEEEKKKT VDLLCSIFPC EVAQQLWQGQ VVQAKKFSNV
     TMLFSDIVGF TAICSQCSPL QVITMLNALY TRFDQQCGEL DVYKVETIGD AYCVAGGLHK
     ESDTHAVQIA LMALKMMELS DEVMSPHGEP IKMRIGLHSG SVFAGVVGVK MPRYCLFGNN
     VTLANKFESC SVPRKINVSP TTYRLLKDCP GFVFTPRSRE ELPPNFPSEI PGICHFLDAY
     QQGTNSKPCF QKKDVEDGNA NFLGKASGID
//
